Scientists Raise Concerns About Revisions to Human Research Regulations

Authors of a new paper take issue with revisions to regulations on biospecimen research enacted last month, and argue that cell lines should be treated differently from other biospecimens.

Katarina Zimmer

| 6 min read

Listen with Speechify

0:00

6:00

ABOVE: © ISTOCK.COM, HEITIPAVES

When Henrietta Lacks visited the Johns Hopkins Medical Center in the 1950s to be treated for cervical cancer, she had no idea that some of her cancer cells would be used to create one of the most scientifically valuable and financially profitable cell lines that is used in labs today. Nor was she asked for permission.

Lacks’s experience has become nationally acknowledged as a shameful episode in the history of biomedical research in the US—particularly after the publication of a popular book about Lacks and her family—and forced the scientific community to consider how to conduct ethical research with human samples. The case was one of the reasons for a heated debate during a recent, six-year-long process of revising the Common Rule, a package of regulations adopted in the 1990s intended to ensure that all federally funded research conducted on human subjects is done ethically.

The ...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member? Login Here

Keywords

Meet the Author

Katarina Zimmer
After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field. Following an internship with The Scientist in 2017, she has been happily freelancing for a number of publications, covering everything from climate change to oncology.
View full profile